Anthracyclines-Induced Cardiac Dysfunction: What Every Clinician Should Know

Chemotherapies have changed the prognosis of patients affected by cancer over last 20 years, with a significant increase in survival rates. However, they can cause serious adverse effects that may limit their use. In particular, anthracyclines, widely used to treat both hematologic cancers and solid cancers, cardiac toxicity, leading development heart failure some cases. This review aims explore current evidence regards anthracyclines’ cardiotoxicity, particular focus on classifications underlying molecular mechanisms, order provide an overview methods its diagnosis, treatment, prevention. An attentive approach prompt management undergoing treatment anthracyclines is imperative avoid preventable antineoplastic drug discontinuation conducive improving short-term long-term cardiovascular morbidity mortality.